- This study investigated chronic subdural hematoma resolution and functional recovery after middle meningeal artery embolization.
- A multicenter retrospective study analyzed 1781 patients with 2295 chronic subdural hematomas treated with embolization.
- Mean hematoma thickness reduced by 64.3%, with 50% resolution in 1.8 months and 80% in 8.9 months.
- The authors concluded that hematoma reduction follows an exponential decay, with resolution extent and timing predicting outcomes.
- Achieving 73% resolution within 90 days is associated with better functional outcomes, providing important prognostic benchmarks.
Chronic Subdural Hematoma: Refining Outcomes with Embolization
Chronic subdural hematoma (cSDH) is a prevalent neurosurgical condition, particularly in aging populations, that often causes significant morbidity [1]. While standard surgical evacuation is common, high recurrence rates have driven interest in adjunctive therapies [2, 3]. Middle meningeal artery embolization (MMAE) has become a widely adopted minimally invasive technique that reduces cSDH recurrence and reoperation rates, both as a standalone treatment and as a surgical adjunct [4, 5, 6, 7]. However, data on its impact on functional outcomes and mortality have been inconsistent across meta-analyses, creating a need for a more granular understanding of its effects [8, 9, 10]. A critical gap remains in defining the expected timeline of hematoma resolution after MMAE and clarifying how these anatomical changes correlate with a patient's functional recovery.
Study Design and Patient Cohort
To map the post-procedural course of cSDH, investigators conducted a large, real-world multicenter retrospective study. The analysis drew from the records of 1781 patients with 2295 cSDHs who underwent MMAE at 24 centers between 2019 and 2024. The cohort reflected the typical demographic for this condition, with a mean age of 72.8 ± 12.4 years and a male predominance (68.1%). To track treatment response, the researchers measured hematoma thickness at baseline and at regular follow-up intervals up to and beyond one year. The pattern of resolution was analyzed using exponential decay functions, a statistical model well-suited for processes like hematoma absorption where the rate of change is proportional to the remaining volume. This method was used to calculate the estimated time to achieve 50% and 80% reduction in hematoma thickness. Patients were also categorized by the final extent of resolution, from complete (≥ 99%) to minimal (< 27%). The primary outcome was functional status, assessed with the Modified Rankin Scale (mRS), where a good functional outcome was defined as an mRS score of 2 or less, indicating no more than slight disability.
Quantifying Hematoma Resolution Dynamics
The study provides clear quantitative benchmarks for hematoma regression following middle meningeal artery embolization. The initial mean hematoma thickness was 15.31 ± 6.53 mm, which decreased to 5.24 ± 5.91 mm by the final follow-up, representing a mean reduction of 64.3% ± 42.1%. The analysis confirmed that this resolution process follows a predictable exponential decay pattern. This mathematical model, where shrinkage is fastest initially and slows as the hematoma gets smaller, provides a reliable framework for predicting the treatment course. Based on this model, the estimated time to achieve a 50% reduction in hematoma thickness was 1.8 months, and the time to reach an 80% reduction was 8.9 months. Nearly half of the patients with complete follow-up, 1031 of 2224 (46.4%), achieved complete resolution, defined as a reduction of 99% or more. These findings establish an expected timeline that can guide both clinician assessment and patient counseling.
Functional Recovery and Prognostic Indicators
The anatomical reduction in hematoma size translated directly into meaningful functional gains for patients. The cohort's median Modified Rankin Scale (mRS) score, a measure of global disability, improved from 1 (interquartile range 0–3) at baseline to 0 (interquartile range 0–2) at follow-up beyond 12 months, indicating a shift toward no residual symptoms. The degree of hematoma resolution was a powerful predictor of this recovery. Good functional outcomes (mRS score ≤ 2) were achieved by 68.9% of patients with complete resolution but only 35.0% of those with minimal resolution (p < 0.001). The speed of resolution was also prognostically significant. Achieving at least 73% resolution within the first 90 days was associated with a higher rate of good outcomes (76.9%) compared to those with slower resolution (67.3%) (p < 0.001). Conversely, the strongest negative predictor was in-hospital neurological deterioration; only 23.7% of patients who experienced neurological deterioration achieved a good outcome, compared to 82.4% of those who did not (p < 0.001). These results suggest that both the extent and the pace of resolution are key indicators of long-term functional prognosis.
Clinical Implications and Future Directions
This large-scale study provides a prognostic roadmap for clinicians managing patients with chronic subdural hematoma after middle meningeal artery embolization. The findings establish that hematoma resolution follows a predictable timeline, with an estimated 50% reduction at 1.8 months and 80% reduction at 8.9 months. This allows physicians to set clear, evidence-based expectations with patients and their families regarding the post-procedural recovery trajectory. The strong correlation between the degree of resolution and functional status provides concrete benchmarks for monitoring treatment efficacy. For example, the finding that achieving over 73% resolution within 90 days is tied to significantly better functional outcomes (p < 0.001) gives clinicians a specific, early timepoint to assess progress. A patient whose hematoma is not resolving along this expected curve may warrant closer surveillance or re-evaluation. Ultimately, these data quantify the link between anatomical changes on imaging and a patient's functional well-being, reinforcing the goals of treatment and providing valuable metrics to guide post-MMAE care.
References
1. Fakhry R, Yeşildal C, Bártek J, et al. Updated systematic review of current randomised controlled trials in chronic subdural haematoma. Acta Neurochirurgica. 2025. doi:10.1007/s00701-025-06683-5
2. Mohammadzadeh I, Hajikarimloo B, Zare A, et al. Efficacy of middle meningeal artery embolization combined with surgery versus standalone surgery for chronic subdural hematoma: a comprehensive systematic review and Meta-Analysis with separate analysis of randomized controlled trials.. Neuroradiology. 2025. doi:10.1007/s00234-025-03777-w
3. Wach J, Vychopen M, Güresir E. Adjunctive role of middle meningeal artery embolization in patients with surgical treatment of unilateral chronic subdural hematoma: a systematic review and meta-analysis of randomized controlled trials.. Frontiers in surgery. 2025. doi:10.3389/fsurg.2025.1623619
4. Παπαγεωργίου Ν, Palaiodimou L, Melanis K, et al. Embolization of Middle Meningeal Artery in Patients with Chronic Subdural Hematoma: A Systematic Review and Meta-Analysis of Randomized-Controlled Clinical Trials. Journal of Clinical Medicine. 2025. doi:10.3390/jcm14092862
5. Wang AP, Shakil H, Ragulojan M, et al. Middle Meningeal Artery Embolization for Subdural Hematoma: Systematic Review and Meta-Analysis of Randomized Trials.. The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques. 2025. doi:10.1017/cjn.2025.10467
6. Gonçalves JPF, Medrado-Nunes GS, Piñeiro GTDO, et al. Adjunct middle meningeal artery embolization versus surgery alone for chronic subdural hematoma: A meta-analysis and trial sequential analysis of randomized controlled trials.. Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia. 2025. doi:10.1016/j.jocn.2025.111307
7. Musmar B, Roy JM, Abdalrazeq H, et al. Comparative outcomes of middle meningeal artery embolization for chronic subdural hematoma: A comprehensive systematic review, meta-analysis, meta-regression and network meta-analysis. Interventional Neuroradiology. 2025. doi:10.1177/15910199251394530
8. Gillespie CS, Veremu M, Cook WH, et al. Middle meningeal artery embolization for chronic subdural hematoma: meta-analysis of three randomized controlled trials and review of ongoing trials. Acta Neurochirurgica. 2025. doi:10.1007/s00701-025-06587-4
9. Kawashima T, Bohoun CA, Uda T. The Efficiency and Safety of Adjuvant Middle Meningeal Artery Embolization in Non-acute Subdural Hematomas: A Systematic Review and Meta-analysis of Randomized Clinical Trials. 2025. doi:10.69854/jcq.2024.0022
10. Monteiro GDA, Mutarelli A, Gonçalves OR, et al. Middle meningeal artery embolization for chronic subdural hematoma: a meta-analysis of randomized controlled trials with trial sequential analysis.. Neurosurgical review. 2025. doi:10.1007/s10143-025-03464-7